Imaging bone morphogenetic protein 7 induced cell cycle arrest in experimental gliomas

Neoplasia

Volumn 13, Issue 3, 2011, Pages 276-285

  Klose, Anke ^a   Waerzeggers, Yannic ^a   Monfared, Parisa ^a   Vukicevic, Slobodan ^b   Kaijzel, Eric L ^c   Winkeler, Alexandra ^a   Wickenhauser, Claudia ^c   Löwik, Clemens W G M ^d   Jacobs, Andreas H ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; LUCIFERASE; RECOMBINANT OSTEOGENIC PROTEIN 1; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 79952365882     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101540     Document Type: Article

References (41)

1. Blumenthal DT and Schulman SF (2005). Survival outcomes in glioblastoma multiforme, including the impact of adjuvant chemotherapy. Expert Rev Neurother 5, 683-690.
2. Gold LI (1999). The role for transforming growth factor-β (TGF-β) in human cancer. Crit Rev Oncog 10, 303-360.
3. Elliott RL and Blobe GC (2005). Role of transforming growth factor β in human cancer. J Clin Oncol 23, 2078-2093.
4. Golestaneh N and Mishra B (2005). TGF-β, neuronal stemcells and glioblastoma. Oncogene 24, 5722-5730.
5. Derynck R and Zhang YE (2003). Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425, 577-584.
6. Akhurst RJ and Derynck R (2001). TGF-β signaling in cancer-a double-edged sword. Trends Cell Biol 11, S44-S51.
7. Massague J (1998). TGF-β signal transduction. Annu Rev Biochem 67, 753-791.
8. Ducy P and Karsenty G (2000). The family of bone morphogenetic proteins. Kidney Int 57, 2207-2214.
9. Feng XH and Derynck R (2005). Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol 21, 659-693.
10. Miyazono K,Maeda S, and Imamura T (2005). BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 16, 251-263.
11. Lee KY and Bae SC (2002). TGF-β-dependent cell growth arrest and apoptosis. J Biochem Mol Biol 35, 47-53.
12. Massague J, Blain SW, and Lo RS (2000). TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309.
13. Weinberg RA (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
14. Wach S, Schirmacher P, Protschka M, and Blessing M (2001). Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members. Oncogene 20, 7761-7769.
15. [] Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, Sundan A, and Borset M(2004). Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23, 3024-3032.
16. Beck SE, Jung BH, Fiorino A, Gomez J, Rosario ED, Cabrera BL, Huang SC, Chow JY, and Carethers JM (2006). Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 291, G135-G145.
17. Franzen A and Heldin NE (2001). BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun 285, 773-781.
18. Ghosh-Choudhury N, Ghosh-Choudhury G, Celeste A, Ghosh PM, Moyer M, Abboud SL, and Kreisberg J (2000). Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim Biophys Acta 1497, 186-196.
19. Miyazaki H, Watabe T, Kitamura T, and Miyazono K (2004). BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 23, 9326-9335.
20. Buijs JT, Henriquez NV, van Overveld PGM, van der Horst G, Que I, Schwaninger R, Rentsch C, ten Dijke P, Cleton-Jansen A-M, Notting IC, et al. (2007). Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Research 67, 8742-8751.
21. Yamada N, Kato M, ten Dijke P, Yamashita H, Sampath TK, Heldin CH, Miyazono K, and Funa K (1996). Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours. Br J Cancer 73, 624-629.
22. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, and Vescovi AL (2006). Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761-765.
23. Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, Kotliarova S, Kotliarov Y, Walling J, Ahn S, et al. (2008). Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastomainitiating cells. Cancer Cell 13, 69-80.
24. Jacobs AH, Winkeler A, Hartung M, Slack M, Dittmar C, Kummer C, Knoess C, Galldiks N, Vollmar S, Wienhard K, et al. (2003). Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Hum Gene Ther 14, 277-297.
25. Vindelov LL, Christensen IJ, Jensen G, and Nissen NI (1983). Limits of detection of nuclear DNA abnormalities by flow cytometric DNA analysis. Results obtained by a set of methods for sample-storage, staining and internal standardization. Cytometry 3, 332-339.
26. [LL, Christensen IJ, Keiding N, Spang-Thomsen M, and Nissen NI (1983). Long-term storage of samples for flow cytometric DNA analysis. Cytometry 3, 317-322.
27. [LL, Christensen IJ, and Nissen NI (1983). Standardization of highresolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry 3, 328-331.
28. Vindelov LL, Christensen IJ, and Nissen NI (1983). A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3, 323-327.
29. Klose A, Wilbrand-Hennes A, Zigrino P, Weber E, Krieg T, Mauch C, and Hunzelmann N (2006). Contact of high-invasive, but not low-invasive, melanoma cells to native collagen I induces the release of mature cathepsin B. Int J Cancer 118, 2735-2743.
30. Desai D, Gu Y, and Morgan DO (1992). Activation of human cyclin-dependent kinases in vitro. Mol Biol Cell 3, 571-582.
31. Saydam O, Glauser DL, Heid I, Turkeri G, Hilbe M, Jacobs AH, Ackermann M, and Fraefel C (2005). Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol Ther 12, 803-812.
32. Abe T, Wakimoto H, Bookstein R, Maneval DC, Chiocca EA, and Basilion JP (2002). Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Ther 9, 228-235.
33. Li H, Lochmuller H, Yong VW, Karpati G, and Nalbantoglu J (1997). Adenovirusmediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. JNeuropathol ExpNeurol 56, 872-878.
34. Prasad G, Wang H, Agrawal S, and Zhang R (2002). Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res 22, 107-116.
35. Yang S, Zhong C, Frenkel B, Reddi AH, and Roy-Burman P (2005). Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 65, 5769-5777.
36. Winkeler A, Sena-Esteves M, Paulis LE, Li H, Waerzeggers Y, Ruckriem B, Himmelreich U, Klein M, Monfared P, Rueger MA, et al. (2007). Switching on the lights for gene therapy. PLoS One 2, e528.
37. Uhrbom L, Nerio E, and Holland EC (2004). Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 10, 1257-1260.
38. Shah K, Tang Y, Breakefield X, and Weissleder R (2003). Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 22, 6865-6872.
39. Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, Contag CH, and Ross BD (2000). Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2, 491-495.
40. Jacobs AH, Rueger MA, Winkeler A, Li H, Vollmar S, Waerzeggers Y, Rueckriem B, Kummer C, Dittmar C, Klein M, et al. (2007). Imaging-guided gene therapy of experimental gliomas. Cancer Res 67, 1706-1715.
41. Kummer C, Winkeler A, Dittmar C, Bauer B, Rueger MA, Rueckriem B, Heneka MT, Vollmar S, Wienhard K, Fraefel C, et al. (2007). Multitracer positron emission tomographic imaging of exogenous gene expression mediated by a universal herpes simplex virus 1 amplicon vector. Mol Imaging 6, 181-192